Accurate detection of cancer-associated molecular abnormalities in tumors could make cancer treatment more personalized. Affibody molecules enable high contrast imaging of tumorassociated proteins expression shortly after injection. The use of the generator-produced positron-emitting radionuclide 68 Ga should increase sensitivity of HER2 imaging. The chemical nature of radionuclides and chelators influence the biodistribution of Affibody molecules, providing an opportunity to further increase the imaging contrast. The aim of the study was to compare maleimido derivatives of DOTA and NODAGA for site-specific
INTRODUCTION
Affibody molecules are small (7 kDa), phage-display derived affinity proteins, which have a substantial potential as imaging agents. 1 They can be selected to bind with high affinity against several cancer-associated molecular abnormalities. 1 Robustness of Affibody molecules permits labeling under harsh conditions. Their small size and high affinity provide good tumor targeting properties and favorable kinetics, therefore permitting acquisition of high contrast images a few hours after injection. 2 The anti-HER2 Affibody molecule Z HER2:342 with high affinity (K D =22 pM) has been developed earlier 3 and is the most studied representative of this class by now. HER2 (human epidermal growth factor receptor type 2) is a transmembrane receptor that is associated with malignant properties in several carcinomas. 4 Signaling of this receptor leads to rapid proliferation, increased motility and suppression of apoptosis. 4. Targeting of the HER2 with the monoclonal antibody trastuzumab or a tyrosine kinase inhibitor lapatinib is one of the successful approaches to prolong survival of metastatic breast cancer patients. 5 Radionuclide molecular imaging of HER2 expression is non-invasive approach for selection of patients for HER2-targeted therapy. Preclinical data confirmed the utility of Z HER2:342 derivatives in imaging of HER2-expressing tumours. 2 In clinics, radiolabeled Affibody molecules demonstrated the capacity of HER2 imaging in breast cancer metastases. 6, 7 Currently, several Affibody molecules for visualization of such cancerassociated molecular targets as EGFR (epidermal growth factor receptor) 8 , IGF1R (insulinlike growth factor 1 receptor) 9 , HER3 (human epidermal growth factor receptor type 3) 10 , and
PDGFRplatelet derived growth factor receptor   are under preclinical evaluation.
The high sensitivity and quantification accuracy of PET would further enhance the utility of 68 Ga provides higher tumor-to-organ ratios than 111 In, when synthetic Affibody molecules were labeled using DOTA conjugated to the N-terminus, 15 or when recombinantly produced Affibody molecules were labeled using maleimido derivatives of NOTA at C-terminus. 18 Recently, we investigated the influence the maleimido derivative of the NODAGA chelator had on the targeting properties of 111 In-labelled Z HER2:2395 (a variant of anti-HER2 Z HER2:342 Affibody molecule having a unique C-terminal cysteine). 22 NODAGA was site-specifically conjugated to Z HER2:2395 using a thiol-directed chemistry and labeled with 111 In. 111 In-NODAGA-Z HER2:2395 demonstrated rapid clearance from the blood with lower uptake in normal organs compared to both DOTA-and NOTA-conjugated counterparts.
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Despite the lower tumor uptake observed, the NODAGA-conjugated variant exhibited the highest tumor-to-organ ratios among all three variants. Superiority of 68 Ga-labelled NODAGA-conjugated peptides over their DOTA-conjugated analogues has been reported for somatostatin analogues 23, 24 and RGD peptides. 25, 26 One might expect that the use of maleimido derivative of NODAGA instead of DOTA would also improve the imaging properties of 68 Ga -labelled Affibody molecules.
The goals of this study were: a) to perform a comparative evaluation of recombinantly produced anti-HER2 Z HER2:2395
Affibody molecule containing a C-terminal cysteine labelled with 68 Ga using maleimido derivatives of NODAGA and DOTA ( Fig. 1) 
MATERIALS AND METHODS

Conjugation and labeling chemistry
Maleimidomonoamido derivatives of NODAGA and DOTA ( Fig.1) were conjugated to Z HER2:2395 Affibody molecule having C-terminal cysteine using a site-specific thiol-directed chemistry as described earlier. 22 111 In was performed as described earlier.
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In vitro studies A study concerning cellular processing of both conjugates labeled with 68 Ga by SKOV3 and DU-145 cells was performed according to the method developed and validated by Wållberg and Orlova. 30 The cells were incubated with 1 nM solution of the labeled compound at 37°C.
At predetermined time points (0.5, 1, 2, and 3 h), cell-bound and internalized radioactivity were determined by an acid wash method. The cells were treated with 0.2 M glycine buffer containing 4 M urea, pH 2.0, for 5 min on ice. The radioactivity in the acid wash fraction was considered as membrane-bound radioactivity. Thereafter, the cells were lysed using 1 M NaOH, and the alkaline fraction was collected. This fraction of radioactivity was considered as internalized. The radioactivity of the samples was measured using an automated γ-counter, and data were normalized to the maximum uptake.
In vivo studies:
The goal of the experiments was a comparative evaluation of the influence of 68 Ga and 111 In labels on biodistribution and targeting properties of MMA-derivatives of DOTA and NODAGA conjugated to Z HER2:2395 . All animal experiments were planned and performed in accordance with national legislation on laboratory animals' protection and were approved by the Local Ethics Committee for Animal Research. In order to reduce the number of animals in the experiments, a dual-label approach was used, i.e. 68 Ga and 111 In-labelled NODAGA-Z HER2:2395 were co-injected in the same mice. The same approach was used with the other conjugate DOTA-Z HER2:2395 . Gamma-spectra of each sample were recorded and uptake of 68 Ga and 111 In were determined by resolving gamma-spectra as it was described earlier. Rompun, 1 mg/mL) followed by heart puncture with a heparinised syringe. Blood and organ samples were collected, weighed and the radioactivity measured as described above. The organ uptake values were calculated as per cent of injected dose per gram of tissue (%ID/g), except for the gastrointestinal tract and the remaining carcass, which were calculated as %ID per whole sample. To check the specificity of xenograft targeting, groups of three mice were subcutaneously pre-injected (neck area) with 500 μg (70 nmol) non-labeled recombinant Z HER2:342 affibody molecule before injecting 111 In/ 68 Ga-NODAGA-Z HER2:2395 or 111 In/ 68 Ga-DOTA-Z HER2:2395 mixture. The control groups were sacrificed at 2 h p.i.
Imaging
To confirm the capacity of the conjugates to visualize HER2-expressing tumors an in vivo imaging experiment was performed. For this purpose, four SKOV-3 xenograft bearing mice were separately injected with 1. Ga-DOTA-Z HER2:2395, respectively (amount of peptide 5 μg). Immediately before imaging, the animals were sacrificed and the urine bladders were excised.
All SPECT/CT and PET/CT studies were performed in The Triumph™ Trimodality system (Gamma Medica, Inc) a fully integrated SPECT/PET/CT hardware and software platform optimized for small animals in pre-clinical applications. Images were acquired 1h p.i. for both the SPECT and PET tracers. SPECT raw data was reconstructed by FLEX TM SPECT software which uses an ordered Subset Expectation Maximization (OSEM) iterative reconstruction algorithm for its pinhole reconstruction. CT raw files were reconstructed by Filter Back Projection (FBP). SPECT/PET and CT data were fused and analysed in PMOD (PMOD Technologies Ltd.).
RESULTS
Labeling
Labeling with 68 Ga was successful under the selected conditions and the average yield was above 95% (range 96-99%).The SDS-PAGE confirmed the identity and purity of 68 Galabelled conjugates (Fig. 2) . 
Stability
In vitro studies
Binding specificity tests demonstrated that the binding of 68 Ga-NODAGA-Z HER2:2395 and 68 Ga-DOTA-Z HER2:2395 to living HER2-expressing cells was receptor-mediated, because presaturation of the receptors by non-labeled Affibody molecule significantly decreased the binding of the radiolabelled Affibody molecule (for both studied cell lines, p<0.0001) ( Table   1 ). The level of cell-associated radioactivity was appreciably lower for non-blocked DU-145 cell line than for SKOV3 cell line, reflecting the lower expression level of HER2.
Data concerning cellular processing of 68 Ga-labeled NODAGA-Z HER2:2395 and DOTA-Z HER2:2395 are presented in Fig. 3 . All conjugates demonstrated similar processing pattern typical for Z HER2:342 and its derivatives. The internalization rate of both conjugates was slow, but internalized radioactivity was increasing throughout the duration of the study. There were, however, some chelator-related differences in internalized radioactivity. 9±1.6% respectively).
In vivo studies
The data concerning biodistribution of 68 Ga and 111 In labeled NODAGA-Z HER2:2395 and DOTA-Z HER2:2395 in female BALB/C nu/nu mice bearing SKOV3 xenografts are presented in Table 2 and Fig. 4 . All conjugates demonstrated highly specific tumor uptake. Pre-saturation of HER2 in tumors by pre-injection of non-labeled Z HER2:342 caused significant (p<0.001%)
reduction of radioactivity accumulation in xenografts for all four conjugates (Fig. 4) . Preblocking did not cause significant differences in radioactivity concentration in normal organs and tissues (data not shown). The tumor uptake values for 68 Ga-DOTA-Z HER2:2395 , 111 In-
DOTA-Z HER2:2395 and 68
Ga-NODAGA-Z HER2:2395 were close to each other (no significant difference), the uptake of 111 In-NODAGA-Z HER2:2395 at both time points was approximately twice lower. All conjugates demonstrated rapid blood clearance and an overall low uptake in non-excretory organs. The low radioactivity level in the gastrointestinal (GI) tract indicated that the hepatobiliary pathway played a minor role in the excretion of all conjugates. The kidney radioactivity was high for all conjugates indicating predominantly renal excretion with subsequent re-absorption of conjugates in the proximal tubuli.
There were clear chelator and nuclide-dependent differences in the biodistribution pattern of the conjugates. The most pronounced was the difference between 111 In-NODAGA-Z HER2:2395 and other conjugates. 111 In-NODAGA-Z HER2:2395 demonstrated significantly more rapid clearance providing significantly lower radioactivity uptake in lung, liver, kidney, gastrointestinal tract and carcass. The renal accumulation of 111 In-NODAGA-Z HER2:2395 was more than two-fold lower in comparison with all other conjugates. The difference between uptake of 68 Ga-NODAGA-Z HER2:2395 and 68 Ga-DOTA-Z HER2:2395 at 2 h p.i. was significant only in liver and spleen.
The data concerning tumor-to-organ ratios are presented in Fig. 5 . 68 Ga-NODAGA-Z HER2:2395 provided at 2h after injection significantly higher tumor-to-liver (8±2 vs. 5.0±0.4) and tumorto-spleen (18±4 vs. 13±1) ratios than 68 Ga-DOTA-Z HER2:2395 . Remarkably, the difference between 111 In-NODAGA-Z HER2:2395 and 111 In-DOTA-Z HER2:2395 was much more pronounced, and 111 In-DOTA-Z HER2:2395 provided significantly higher tumor-to-blood, tumor-to-lung, tumor-to-liver, tumor-to-spleen and tumor-to-bone ratios.
Images acquired 1h after the i.v. injection for the four conjugates into mice bearing SKOV3 xenografts confirmed the capacity of radiolabeled Z HER2:2395 derivatives to visualize HER2 expression (Fig. 6 ). In agreement with the biodistribution data, a prominent radioactivity uptake was observed in kidneys. No noticeable accumulation of radioactivity in other healthy organs and tissues was observed.
DISCUSSION
The use of PET should further increase the sensitivity of imaging using Affibody molecules. This is essential for visualization of small metastases. Emerging production of GMP-grade 68 Ga generators suggests that the use of 68 Ga as a label might be a way of clinical implementation of Affibody-based PET. Earlier, a number of Affibody variants conjugated with macrocyclic chelators were labeled with 111 In and characterized pre-clinically. These previous studies have demonstrated that both the chemical nature of chelator and conjugation linker, as well as the site of its conjugation to the Affibody molecule influence substantially the clearance rate of conjugates from blood, and their uptake in normal tissues and in tumours. [20] [21] [22] 31 This opens a way to improve targeting. As much as two-fold increase of tumor-to-blood and tumor-to-organ ratios might be gained by optimization of the chelator nature and position in the case of 111 In. [20] [21] [22] 31 One might consider that substitution of 111 In with 68 Ga in such conjugates could be a straightforward approach requiring only some reoptimization of labeling conditions. However, although both gallium and indium are trivalent metals, they differ appreciably in coordination geometry 32 resulting in different physicochemical properties of chelates. While difference in biodistribution of 111 In and 68 Galabeled short peptides is quite well studied, 23, 33, 34 only limited information is available for Affibody molecules. 15, 18 In this study, we evaluated Affibody molecules site-specifically coupled at the C-terminus with two different chelators (DOTA and NODAGA) through thioldirected chemistry. The conjugates are labeled with 68 Ga and compared in a dual-isotope study with 111 In.
This study demonstrates that conjugation of maleimido derivatives of DOTA and NODAGA to a unique cysteine at the C-terminus permits site-specific and stable labeling of Affibody molecules with 68 Ga. These tracers preserved the capacity to specifically bind HER2-expressing cells in vitro ( Table 1) . The internalization assay of 68 Ga-NODAGA-Z HER2:2395 and 68 Ga-DOTA-Z HER2:2395 showed that internalization rate is slow (Fig. 3) , which is typical for anti-HER2 Affibody molecules. 15, 18, 27 Interestingly, the internalization by SKOV-3 cells (high HER2 expression) had nearly equal rate for both conjugates (11±1 vs 9±2% after 3 h incubation). However, this was not the case in DU145 cells (low HER2 expression), where 68 Ga-DOTA-Z HER2:2395 demonstrated a two-fold higher internalized fraction compared to 68 Ga-NODAGA-Z HER2:2395 (21±4 vs 11±3%, respectively). Earlier, we have found that binding of anti-HER2 Affibody molecules to HER2-receptors on DU145 (but not on SKOV3 cell) in vitro might be influenced by co-expression with EGFR, presumably by heterodimerization. 35 It is possible that binding of 68 Ga-DOTA-Z HER2:2395 and 68 Ga-NODAGA-Z HER2:2395 influences differently heterodimerization of HER2 and EGFR on DU-145 cells, which might explain difference in internalization rate.
Both 68 Ga-DOTA-Z HER2:2395 and 68 Ga-NODAGA-Z HER2:2395 targeted HER2-expressing xenografts in mice specifically (Fig.4) and were capable to visualize HER2-expressing xenografts with high contrast already at 1 h after injection (Fig.6) . However, the tumor-toorgan ratios for both conjugates increased appreciably by 2 h after injection (Fig. 5) . It would make sense to perform imaging at 2 h in clinical practice to visualize small metastases with higher contrast. The 68-min half-life of 68 Ga would permit this. Importantly, the biodistribution properties of 68 Ga-NODAGA-Z HER2:2395 provided significantly higher tumorto-liver and tumor-to-spleen ratios in comparison with 68 Ga-DOTA-Z HER2:2395 . Thus, the use of maleimido derivative of NODAGA for labeling of Affibody molecules with 68 Ga may improve detection of liver metastases. This is important, as liver is a frequent metastatic site for a number of HER2-expressing cancers, including breast carcinoma. 36 It has to be noted that the biodistribution pattern of 111 In-labeled Affibody molecules was not quite predictive for the biodistribution of 68 Ga-labelled counterparts. Uptake of both 68 Galabelled tracers in liver and spleen was significantly higher than 111 In-labelled. Further, the uptake of 111 In-NODAGA-Z HER2:2395 was significantly lower than uptake of 111 In-DOTA-Z HER2:2395 in the majority of tissues, including tumors and kidneys. These results were concordant with our previous data for targeting of DU145 with low HER2 expression, 22 although the magnitude of the effect was different, presumably due to differences in mouse strain, sex and HER2-expression level in xenografts. Particularly, previous studies 37 have demonstrated that clearance of Affibody molecules from blood is slower in the case of high HER2 expression in tumors, most likely because tumors act as depot for reversibly bound conjugates. The difference in 68 Ga-labelled Affibody molecules uptake was limited to liver and spleen. Overall, while DOTA-Z HER2:2395 provided the best tumor-to-organ ratios for 111 In label in the model with high HER2 expression, NODAGA-Z HER2:2395 was the best for 68 Ga.
Interestingly, earlier study has shown that for synthetic Affibody molecule labeled via DOTA conjugated to N-terminus using amide bond, 68 Ga provides equal liver uptake with 111 In. 15 In this study, uptake of 68 Ga was twice higher than 111 In. This indicates that both position of a chelator in Affibody molecules and conjugation chemistry might influence biodistribution profile of the imaging agent. Thus assessment of different combinations of radionuclides and chelators is necessary for optimization of scaffold-protein-based imaging agents. Currently, several Affibody molecules are under development as imaging agents for other cancerassociated molecular targets (e.g. EGFR, IGF-1R, PDGFR). 1 Moreover, several other scaffold proteins with similar size are evaluated as probes for radionuclide molecular imaging. 38 Our finding should be useful for the development of such probes.
In conclusion, the results of this study suggest that selection of chelators influences biodistribution and imaging properties of Affibody molecules. The use of maleimido derivative of NODAGA instead of DOTA permits an increase of tumor-to-liver and tumor-tospleen ratios of 68 Ga-labelled Affibody molecules in case of placement of the label at Cterminus. This can be essential for PET visualization of e.g. small liver metastases. The influence of chelators depends of radionuclides used as labels. Thus, biodistribution data obtained for a scaffold protein conjugate using one nuclide cannot be used for exact prediction of behavior of the same conjugate labeled with another one. This is essential information for the development of imaging conjugates based on scaffold proteins.
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